Thais Aragão Horoiwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thais Aragão Horoiwa has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adriano Marim de Oliveira
Bionanomanufacturing Center, Technological Research Institute, São Paulo 05508-070, SP, Brazil
5 shared publications - Natália Neto Pereira Cerize
Institute for Technological Research (IPT)−Bionanomanufacturing Center (BIONANO)
4 shared publications Amanda Migotto
Institute of Biomedical Sciences - University of São Paulo - Department of Parasitology - Av. Prof. Lineu Prestes, 1374 - Edifício Biomédicas II, Cidade Universitária - São Paulo - SP - 05508-000 - Brazil
2 shared publications- Amy Cameron
Frazer Institute The University of Queensland Brisbane QLD Australia
1 shared publication - Bijun Zeng
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
1 shared publication Carla Letícia Bandeira
Institute of Biomedical Sciences - University of São Paulo - Department of Parasitology - Av. Prof. Lineu Prestes, 1374 - Edifício Biomédicas II, Cidade Universitária - São Paulo - SP - 05508-000 - Brazil
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (6) , e70110
Control of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells
Objectives: Cancer vaccines combine tumor antigen and adjuvant to drive an anti‐tumor immune response. Clec9A‐targeted nanoparticles directing CD4 and CD8 neo‐epitopes to cross‐presenting dendritic cells (DCs) stimulate adjuvant‐free therapeutically effective tumor‐specific immunity. However, personalised neo‐epitopes limit the scalability of Clec9A nanoparticles for clinical translation. Since Clec9A + DCs constitutively present relevant neoepitopes in tumors but are suppressed in tumor microenvironments, we developed Clec9A‐targeted STING or RIG‐I liposomes to enhance endogenous tumor immunity. Methods: Liposomes encapsulating RIG‐I or the STING agonist MSA‐1 and functionalised with Clec9A binding peptide WH were optimised for uptake by Clec9A + conventional and plasmacytoid DCs in vivo . Biodistribution after i.v. administration was determined with in vivo imaging and cellular uptake and activation with flow cytometry. Plasma was analysed for type 1 interferon (IFN) by ELISA and liver, spleen, tumor, blood, kidney, heart and tumor draining lymph node transcriptomes were analysed with Nanostring. Effects on tumor growth and survival, and tumor‐specific T cells were evaluated using the B16 melanoma model. Results: Clec9A‐targeting liposomes administered i.v. were distributed to spleen, liver and tumor and were taken up by cross‐presenting and plasmacytoid DCs. Type 1 IFN production and DC, B‐ and T‐cell activation were more effective with i.v. Clec9A‐STING than Clec9A‐RIG‐I liposomes. Intravenous Clec9A‐STING liposomes stimulated IFN‐dependent transcription in blood, lung, tumor, and draining lymph nodes. Intravenous Clec9A‐STING liposomes, or intra‐tumoral Clec9A‐RIG‐I liposomes significantly suppressed B16‐F10 melanoma growth and induced neo‐epitope and survivin‐specific CD4 + and CD8 + T‐cell responses. Conclusions: Clec9A‐STING liposomes are a scalable, translatable tumor‐targeted immunotherapy platform.
- 1 June 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (6) , e70110
Open AccessControl of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells
Objectives: Cancer vaccines combine tumor antigen and adjuvant to drive an anti‐tumor immune response. Clec9A‐targeted nanoparticles directing CD4 and CD8 neo‐epitopes to cross‐presenting dendritic cells (DCs) stimulate adjuvant‐free therapeutically effective tumor‐specific immunity. However, personalised neo‐epitopes limit the scalability of Clec9A nanoparticles for clinical translation. Since Clec9A + DCs constitutively present relevant neoepitopes in tumors but are suppressed in tumor microenvironments, we developed Clec9A‐targeted STING or RIG‐I liposomes to enhance endogenous tumor immunity. Methods: Liposomes encapsulating RIG‐I or the STING agonist MSA‐1 and functionalised with Clec9A binding peptide WH were optimised for uptake by Clec9A + conventional and plasmacytoid DCs in vivo . Biodistribution after i.v. administration was determined with in vivo imaging and cellular uptake and activation with flow cytometry. Plasma was analysed for type 1 interferon (IFN) by ELISA and liver, spleen, tumor, blood, kidney, heart and tumor draining lymph node transcriptomes were analysed with Nanostring. Effects on tumor growth and survival, and tumor‐specific T cells were evaluated using the B16 melanoma model. Results: Clec9A‐targeting liposomes administered i.v. were distributed to spleen, liver and tumor and were taken up by cross‐presenting and plasmacytoid DCs. Type 1 IFN production and DC, B‐ and T‐cell activation were more effective with i.v. Clec9A‐STING than Clec9A‐RIG‐I liposomes. Intravenous Clec9A‐STING liposomes stimulated IFN‐dependent transcription in blood, lung, tumor, and draining lymph nodes. Intravenous Clec9A‐STING liposomes, or intra‐tumoral Clec9A‐RIG‐I liposomes significantly suppressed B16‐F10 melanoma growth and induced neo‐epitope and survivin‐specific CD4 + and CD8 + T‐cell responses. Conclusions: Clec9A‐STING liposomes are a scalable, translatable tumor‐targeted immunotherapy platform.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Materials Research
- Vol. 22 (2)
Process Evaluation of Sugar-Based Polymeric Colloidal Nanocarrier Formation
Several studies have demonstrated that sugar-based nanocarriers are recommended to develop drug delivery systems since they are biocompatible and biodegradable and might improve the therapeutic index of currently used drugs by reducing their toxicity and enhancing their bioavailability. Therewith, this work studied the processing conditions to formation of a sugar-based nanocarrier denominated polymeric colloidal nanocarriers (PCN). It reports the impact of emulsifiers types and concentration, salt concentration and copolymers addition on physical stability and particle size distribution of a maltodextin-based PCN. In order to define the most stable formulation to produce the maltodextrin nanocarriers, 13 PCN formulations were evaluated in respect to kinetic stability, particle size distribution and morphology. The results demonstrated that to have a stable sugar-based PCN in silicone for at least 3 days, it is necessary to work with Poloxamer 188 as a copolymer, SF 1540 surfactant in a concentration proportional to the solid content and a salt concentration of 0.4 %.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Materials Research
- Vol. 22 (2)
Open AccessProcess Evaluation of Sugar-Based Polymeric Colloidal Nanocarrier Formation
Several studies have demonstrated that sugar-based nanocarriers are recommended to develop drug delivery systems since they are biocompatible and biodegradable and might improve the therapeutic index of currently used drugs by reducing their toxicity and enhancing their bioavailability. Therewith, this work studied the processing conditions to formation of a sugar-based nanocarrier denominated polymeric colloidal nanocarriers (PCN). It reports the impact of emulsifiers types and concentration, salt concentration and copolymers addition on physical stability and particle size distribution of a maltodextin-based PCN. In order to define the most stable formulation to produce the maltodextrin nanocarriers, 13 PCN formulations were evaluated in respect to kinetic stability, particle size distribution and morphology. The results demonstrated that to have a stable sugar-based PCN in silicone for at least 3 days, it is necessary to work with Poloxamer 188 as a copolymer, SF 1540 surfactant in a concentration proportional to the solid content and a salt concentration of 0.4 %.
- 1 January 2017
- Published by Even3 in Revista IPT: Tecnologia e Inovação
- Vol. 1 (4)
Development of polymeric colloidal nanocarrier based on maltodextrin
Development of polymeric colloidal nanocarrier based on maltodextrin
- 1 January 2017
- Published by Even3 in Revista IPT: Tecnologia e Inovação
- Vol. 1 (4)
Development of polymeric colloidal nanocarrier based on maltodextrin
Development of polymeric colloidal nanocarrier based on maltodextrin
- 1 January 2017
- Published by Even3 in Revista IPT: Tecnologia e Inovação
- Vol. 1 (4)
Avaliação da contribuição de copolímero de bloco PEG/PPG na estabilidade coloidal de nanocarreadores
Avaliação da contribuição de copolímero de bloco PEG/PPG na estabilidade coloidal de nanocarreadores
- 1 January 2017
- Published by Even3 in Revista IPT: Tecnologia e Inovação
- Vol. 1 (4)
Avaliação da contribuição de copolímero de bloco PEG/PPG na estabilidade coloidal de nanocarreadores
Avaliação da contribuição de copolímero de bloco PEG/PPG na estabilidade coloidal de nanocarreadores
- 1 October 2014
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Water-in-diesel nanoemulsion by LTCC microfluidic devices
In this work we present the first results related to production of water nanoemulsion in diesel oil using microfluidic reactors as tool. We tested two different microreactors, a vortex and 3D serpentine geometry, varying parameters such as total flow rate, surfactant concentration and ratio between phases. It was observed water droplets sizes from 100 to 700 nm, and the stability was dependent of surfactant concentration. Higher flow rates offer smaller droplets sizes obtained in vortex device. However, with 3D serpentine we observed nanoemulsion with better stability.
- 1 October 2014
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Water-in-diesel nanoemulsion by LTCC microfluidic devices
In this work we present the first results related to production of water nanoemulsion in diesel oil using microfluidic reactors as tool. We tested two different microreactors, a vortex and 3D serpentine geometry, varying parameters such as total flow rate, surfactant concentration and ratio between phases. It was observed water droplets sizes from 100 to 700 nm, and the stability was dependent of surfactant concentration. Higher flow rates offer smaller droplets sizes obtained in vortex device. However, with 3D serpentine we observed nanoemulsion with better stability.